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The central nervous system (CNS) is an important and
increasingly recognized site of treatment failure in
anaplastic lymphoma kinase (ALK)-positive, non–small cell
lung cancer (NSCLC) patients receiving ALK inhibitors. In
this report, we describe two ALK-positive patients who
experienced initial improvements in CNS metastases on
standard dose alectinib (600 mg twice daily), but who sub-
sequently experienced recurrences with symptomatic lep-
tomeningeal metastases. Both patients were dose-escalated
to alectinib 900 mg twice daily, resulting in repeat clinical
and radiographic responses. Our results suggest that dose
intensiﬁcation of alectinib may be necessary to overcome
incomplete ALK inhibition in the CNS and prolong the
durability of responses in patients with CNS metastases,
particularly those with leptomeningeal carcinomatosis.
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Central nervous system (CNS)metastases are frequent
complications of anaplastic lymphoma kinase (ALK)-
positive lung cancer, affecting nearly 30% of newly
diagnosed metastatic patients.1 Among ALK-positive pa-
tients treated with the ALK inhibitor crizotinib, the CNS is
a common site of relapse.2 Among crizotinib-resistant
patients enrolling in clinical trials of second-generationJournal of Thoracic Oncology Vol. 11 No. 2: 256-260ALK inhibitors, the frequency of CNS metastases is
approximately 60%.3,4 Recently, it has also been observed
that such relapses may include leptomeningeal and
intramedullary metastases.5 Together, these complica-
tions are major causes of morbidity and mortality for
patients with ALK-positive non–small cell lung cancer
(NSCLC).
Alectinib is a second-generation ALK inhibitor that
has shown signiﬁcant antitumor activity in patients with
ALK-positive NSCLC. In a phase I study conducted in the
United States, alectinib was associated with an objective
response rate (ORR) of 55% in patients who had been
previously treated with crizotinib.6 Similar antitumor
activity was observed in a recent global phase II study of
alectinib.3 Among 122 patients with crizotinib-resistant,
ALK-positive NSCLC, alectinib produced an ORR of 50%
Figure 1. Sagittal T1-weighted postgadolinium magnetic resonance imaging scans of the thoracic spine of a patient with
anaplastic lymphoma kinase–positive non–small cell lung cancer who was treated with alectinib. (A) Leptomeningeal
enhancement along the surface of the thoracic spinal cord (red arrow) and an intramedullary metastasis at the level of T11
(blue arrow) before alectinib treatment. (B) Interval improvement in leptomeningeal enhancement and resolution of an
intramedullary T11 metastasis after two months of alectinib 600 mg twice daily. (C) Worsening intramedullary enhancement
(red arrow) in the thoracic spinal cord after six months of alectinib (600 mg twice daily). (D) Interval improvement in
intramedullary enhancement in the thoracic spinal cord after dose escalation of alectinib to 900 mg twice daily.
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Alectinib has also shown impressive activity in patients
with CNS metastases, including intracranial objective
response rates of 42.9% to 52%.3,6 Importantly, alectinib
has also produced responses in patients with lep-
tomeningeal disease7,8—a clinical feature that histori-
cally portends a dismal prognosis in NSCLC (median
overall survival, w12 weeks).9 Based upon these
encouraging early results, alectinib has been granted
breakthrough therapy designation by the US Food and
Drug Administration for patients with ALK-positive
NSCLC who have been previously treated with crizotinib.
Case 1
We previously reported the case of a 56-year-old man
with metastatic, ALK-positive NSCLC that was compli-
cated by leptomeningeal metastases.7 He received
sequential treatment with crizotinib, the second-
generation ALK inhibitor ceritinib, and whole brain radi-
ation therapy (WBRT), but subsequently recurred with
leptomeningeal metastases (Fig. 1A). Thereafter, he beganalectinib, achieving a rapid clinical and radiographic
response (Fig. 1B). Six months after starting alectinib,
however, the patient developed recurrent word-ﬁnding
difﬁculties, gait imbalance, and progressive fatigue.
Repeat neuroimaging revealed patchy, diffuse intra-
medullary enhancement in the thoracic spinal cord and
enhancement along the surface of the cervical and
thoracic cord, consistentwith progressive leptomeningeal
carcinomatosis (Fig. 1C). Given the absence of alternative
effective treatments, the patient was dose-escalated from
600 mg to 900 mg alectinib twice daily. Within several
weeks, he experienced signiﬁcant improvements in bal-
ance, cognition, and speech. A repeat magnetic resonance
imaging (MRI) scan of his spine performed two months
later showed interval improvement in intramedullary and
leptomeningeal enhancement (Fig. 1D). His systemic dis-
ease remained stable. From the point of initial dose
escalation, the patient remained on alectinib 900 mg
twice daily with continued response for a total of six
months, atwhich time hewas found to have asymptomatic
progression in the leptomeninges. Alectinib was well
Figure 2. Coronal T1-weighted postgadolinium magnetic resonance imaging scans of a patient with anaplastic lymphoma
kinase–positive non–small cell lung cancer. (A) Note the focus of leptomeningeal enhancement in the left mesial temporal
lobe (red arrow) that developed on alectinib 600 mg twice daily. (B) Near complete interval resolution of leptomeningeal
enhancement after 4 weeks of alectinib 900 mg twice daily.
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only one noted side effect (grade 1 constipation).Case 2
Case 2 involves a 34-year-old man with ALK-
rearranged NSCLC complicated by brain and osseous
metastases at the time of initial diagnosis. After
completion of WBRT and palliative radiotherapy to the
right ilium, the patient began ﬁrst-line crizotinib. He
remained on crizotinib for approximately two years,
during which time he underwent a craniotomy with
metastatectomy and palliative radiotherapy to several
painful osseous metastases. In December 2013, he dis-
continued crizotinib and began carboplatin and peme-
trexed. After two cycles of chemotherapy, treatment was
interrupted for stereotactic radiosurgery to four brain
metastases.
In July 2014, the patient enrolled on a phase I/II trial
of alectinib (NCT01871805). He responded systemically
to a dose of 600 mg twice daily. In May 2015, however,
the patient was hospitalized with headaches and confu-
sion and was found to be in nonconvulsive, status epi-
lepticus. A MRI scan of his brain at that time revealed
interval development of new focal leptomeningeal
enhancement at multiple sites (Fig. 2A), consistent with
CNS progression. The patient was started on corticoste-
roids and he ultimately required three antiepileptic
drugs to control his seizures. Upon discharge, he had
improvement in symptoms; however, he had moderate
cognitive dysfunction, including aphasia and short-term
memory loss. After discussions with the study sponsor,
the decision was made to dose-escalate alectinib to 900
mg twice daily. Within one month, the patient and his
family reported signiﬁcant improvements in headaches,cognition, word-ﬁnding ability, and memory. The patient
was able to taper his corticosteroids to a minimal dose. A
repeat MRI scan of the brain approximately 4 weeks
later (at the escalated dose) revealed near complete
resolution of the leptomeningeal enhancing foci (Fig. 2B).
The patient has remained on alectinib 900 mg twice
daily for 3.5 months with an ongoing response. In gen-
eral, dose-escalated alectinib was well tolerated. Adverse
events related to alectinib included transient grade 3
hypophosphatemia and grade 1 fatigue, constipation,
and dyspepsia.Discussion
Historically, dosing of targeted therapies in oncology
has typically followed a one size ﬁts all approach, with
dose reductions for toxicities. However, there is prece-
dent for dose-escalation strategies after treatment fail-
ure. For example, in patients with chronic myeloid
leukemia, imatinib dose escalation was a common
treatment approach in patients progressing on therapy
before the development of second-generation BCR-ABL
inhibitors.10 Similarly, imatinib dose escalation has also
been explored at the time of disease progression in pa-
tients with gastrointestinal stromal tumors.11 In patients
with NSCLC, “pulsatile” dosing of the epidermal growth
factor receptor (EGFR) inhibitor erlotinib has been
investigated in EGFR-mutant patients with lep-
tomeningeal metastases based upon concerns for inad-
equate CNS penetration with standard dosing.12 This
strategy, either alone or in combination with low-dose
daily erlotinib, has demonstrated activity in EGFR-
mutant patients with CNS metastases.13,14
Similar to the experience with pulsed-dose erlotinib,
the two cases outlined above show the potential
February 2016 Alectinib Dose-Escalation In the CNS 259importance of dose intensiﬁcation of alectinib in patients
with ALK-positive disease affecting certain sanctuary
sites, such as the CNS. In a phase I dose-ﬁnding study of
alectinib that was conducted in the United States, a
maximum tolerated dose was not identiﬁed.6 Ultimately,
a recommended phase 2 dose (RP2D) of 600 mg twice
daily was selected based upon combined safety, efﬁcacy,
and pharmacokinetic data. However, doses up to 900 mg
twice daily were also explored. Notably, alectinib 900 mg
twice daily was associated with numerically higher peak
concentrations and exposure levels over time compared
to the RP2D. Speciﬁcally, at a dose of 900 mg twice daily,
the mean (± SD) maximal plasma concentration (Cmax)
and area under the plasma concentration-time curve
(AUC0–10) were 1140 ± 448 ng/mL and 9840 ± 4620
ng  hr/mL, respectively. By contrast, at the RP2D of
600 mg twice daily, the mean Cmax and AUC0–10 were
676 ± 186 ng/mL and 5400 ± 1400 ng  hr/mL,
respectively. Among 13 patients treated in the 900 mg
twice daily cohort in this phase I trial, dose-limiting
toxicities (DLTs) were reported in two patients. DLTs
included grade 3 headache and grade 3 neutropenia
requiring a dose delay of 7 days. Both patients remained
on study, and each DLT resolved after dose reduction. Of
note, among the two patients detailed in our report
above, alectinib 900 mg twice daily was generally well-
tolerated with no signiﬁcant adverse events.
In animal models, alectinib produces relatively high
brain:plasma ratios, ranging from 0.63 to 0.94.15 Clini-
cally, measurable concentrations of alectinib have also
been detected in cerebrospinal ﬂuid (CSF) samples ob-
tained from ALK-positive patients who were treated with
alectinib.6 For example, in the report by Gadgeel et al.,6
ﬁve ALK-positive patients with CNS metastases had
paired CSF and plasma samples available for analysis,
revealing an apparent linear correlation between con-
centrations of free alectinib in the CSF and serum.6
Nonetheless, CNS concentrations of alectinib did not
appear fully equivalent to systemic drug levels in
the above studies. Our report reinforces these observa-
tions and suggests that inadequate ALK inhibition by
alectinib may still underlie CNS disease progression in
some patients.
Notably, despite a clinical and radiographic repeat
response to dose-escalated alectinib in case 1, the pa-
tient ultimately developed disease progression after six
months. In addition to pharmacokinetic considerations,
various molecular mechanisms of resistance to ALK in-
hibitors have been described. In particular, several ALK
resistance mutations (e.g., G1202R, V1180L, and I1171
missense mutations) have been shown to confer resis-
tance to alectinib.16,17 In case 1, however, the patient
experienced CNS-only progression. We were unable to
obtain a second biopsy specimen to evaluate for ALKresistance mutations or other molecular mechanisms of
resistance. Moving forward, emerging technologies that
allow for the detection of cell-free DNA in the circula-
tion18 or CSF19 may provide insights into molecular
mechanisms of resistance in such cases. In time, this may
also inform therapeutic decision making including the
relative roles of additional systemic therapy versus
radiotherapy for CNS disease.
In summary, our ﬁndings suggest that dose intensiﬁ-
cation of alectinib may be helpful in prolonging the dura-
bility of responses in patients with CNS metastases,
particularly those with leptomeningeal metastases. Addi-
tional investigation of this strategy may be warranted.
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